Strategies for Updated Treatment Options for IPF

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2016 Fall Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 1, 2017 to December 31, 2017

Instructions for CME/CNE: Listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.  To print or save your certificate, you will need to click on the “download” button and either print or save.

These presentations require Adobe Flash Player.  You can download it here.
 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Boehringer Ingelheim Pharmaceuticals

PLEASE CLICK HERE TO VIEW THE PRESENTATION IN FLASH

PLEASE CLICK HERE TO VIEW THE PRESENTATION IN HTML5

PLEASE CLICK HERE FOR EVALUATION and POST-TEST

Description
Idiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic interstitial pneumonias, and is a devastating disease associated with irreversible destruction of the lung. There are more than 80,000 adults in the US that have IPF and more than 30,000 cases are diagnosed each year, being more common in men than in women. IPF typically has a poor prognosis with a median survival of 3 years, thus it is imperative that clinicians diagnosis the disease early in order to implement appropriate management options to control symptoms and slowing of the disease progression to best maintain patient quality of life. Although there is no cure for IPF, there are numerous treatment options that have become available in the past several years. These options include corticosteroids, proton pump inhibitors, antioxidants and immune suppressants. There have also been advances in the pharmacological management which include nintedanib and pirfenidone. These effective therapies have shown improvement in a patient’s quality of life by slowing the progression of the lung tissue damage. Recent clinical trials have identified new treatments for this disease which lead to the approval of new therapeutic options by the FDA. The education of healthcare professionals will help with the appropriate use of current and newly approved medications as well as giving effective management strategies.

Upon Completion of this activity, participants will be able to:

  • Analyze the safety and efficacy of current and emerging therapies for idiopathic pulmonary fibrosis (IPF) including those in late stages of clinical development

  • Discuss effective diagnostic methods for IPF, using the appropriate imaging modalities and other methods to facilitate earlier treatment options

  • Discuss current and emerging pharmacologic treatment options for IPF

  • Assess personalized treatment plans to address risk, adverse events, and overall quality of life for patients with IPF

  • Describe effective strategies with a multidisciplinary approach to the management of IPF and associated comorbidities
     

Faculty: Paul Noble, MD
Chair Department of Medicine
Director, Women's Guild Lung Institute
Cedars-Sinai

Disclosure:

Dr. Noble serves as a consultant to Boehringer Ingelheim and Genentech/Roche. His presentation has been peer reviewed.
 
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jacquelyn Smith, RN, BSN, MA, CMCN has no real or perceived financial relationships to disclose.
Katie Eads has no real or perceived financial relationships to disclose.
Will Williams has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

The National Association of Managed Care Physicians designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Nurses who complete this activity and turn in a validation form will receive up to 1 credit in continuing nursing education.

The American Board of Managed Care Nurses has approved this activity for a maximum of 1 contact hour towards CMCN recertification.

This presentation is supported by an educational grant from
Boehringer Ingelheim Pharmaceuticals

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.